Medtronic Acquires SPR Therapeutics for $650 Million
The acquisition adds SPR’s FDA-cleared SPRINT PNS System, a short-term percutaneous peripheral nerve stimulation (PNS) therapy, to Medtronic’s pain therapy portfolio.
The acquisition adds SPR’s FDA-cleared SPRINT PNS System, a short-term percutaneous peripheral nerve stimulation (PNS) therapy, to Medtronic’s pain therapy portfolio.
The acquisition strengthens Medtronic’s neurovascular portfolio by adding Scientia’s advanced access technologies, including guidewires and catheters.
The Hugo RAS system has already received FDA clearance for urologic surgical procedures, and Medtronic has now submitted new 510(k) filings seeking expanded approval for its use in general surgery and gynecological procedures.
Retia Medical expands partnership with Medtronic to distribute its hemodynamic system, Argos Cardiac Output Monitor, in Western Europe.